Please use this identifier to cite or link to this item:
Title: Use of neuraminidase inhibitors to combat pandemic influenza.
Authors: Democratis, J
Pareek, M
Stephenson, I
First Published: Nov-2006
Citation: J ANTIMICROB CHEMOTHER, 2006, 58 (5), pp. 911-915
Abstract: Since the last influenza pandemic in 1968, neuraminidase (NA) inhibitors have been licensed for the treatment and prophylaxis of seasonal influenza. Continuing outbreaks of highly pathogenic avian influenza H5N1 since 2004 have focused attention on the timing of the next pandemic and preparedness plans. Although immunization is the principal means of influenza prophylaxis, a well-matched efficacious vaccine is unlikely to be widely available for several months following the emergence of the pandemic strain. NA inhibitors could be used to contain and eliminate an emerging pandemic virus at source. If unsuccessful, they could still play a crucial role in reducing the medical impact of pandemic influenza as it spreads through countries. Accordingly, many authorities are creating stockpiles of NA inhibitors. However, the use of stockpiled drugs for treatment or prophylaxis, the rapid delivery to newly diagnosed cases and unknown characteristics of an emergent pandemic strain pose significant challenges to determining optimal use of stockpiles.
DOI Link: 10.1093/jac/dkl376
ISSN: 0305-7453
Type: Journal Article
Appears in Collections:Published Articles, Dept. of Infection, Immunity and Inflammation

Files in This Item:
There are no files associated with this item.

Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.